Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 18, 2025; 15(4): 107461
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.107461
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.107461
Serum factor V and arterial lactate levels predict graft survival in liver transplant recipients with aminotransferase above five thousand
Gabriel Lazzarotto-da-Silva, Flávia Heinz Feier, Pablo Duarte Rodrigues, Tomaz Jesus Maria Grezzana-Filho, Marcio Fernandes Chedid, Cleber Rosito Pinto Kruel, Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Rio Grande do Sul, Brazil
Bruno Marches Chaves, Department of Digestive Surgery, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Rio Grande do Sul, Brazil
Alexandre de Araujo, Roberta Cabral Marchiori, Department of Gastroenterology and Hepatology, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Rio Grande do Sul, Brazil
Mario Reis Alvares-da-Silva, Division of Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-007, Rio Grande do Sul, Brazil
Author contributions: Lazzarotto-da-Silva G and Chedid MF participated in the research design, data collection, data analysis, and writing of the manuscript; Rodrigues PD, Feier FH, Grezzana-Filho TJM, de Araujo A, Alvares-da-Silva MR, Marchiori RC, and Kruel CRP participated in the research design and revision of the final version of the manuscript; all of the authors read and approved the final version of the manuscript to be published.
Supported by Financiamento e Incentivo à Pesquisa of Hospital de Clínicas de Porto Alegre, No. 170271.
Institutional review board statement: This study complies with ethical standards and was approved by the Hospital de Clínicas de Porto Alegre Institutional Review Board.
Informed consent statement: Informed consent was waived by the ethics committee because this was an observational retrospective study.
Conflict-of-interest statement: All authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marcio Fernandes Chedid, MD, PhD, Professor, Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Porto Alegre 90035-007, Rio Grande do Sul, Brazil. mchedid@hcpa.edu.br
Received: March 24, 2025
Revised: April 13, 2025
Accepted: May 21, 2025
Published online: December 18, 2025
Processing time: 240 Days and 11 Hours
Revised: April 13, 2025
Accepted: May 21, 2025
Published online: December 18, 2025
Processing time: 240 Days and 11 Hours
Core Tip
Core Tip: Among 341 liver transplant recipients, 25 had an aminotransferase level > 5000 U/L. Early allograft failure (death or re-transplantation within 90 days) occurred in 11 patients. One-year and five-year graft survival rates were 51.7% and 42.6%, respectively. However, approximately 50% of these patients withstood initial graft injury and had a satisfactory long-term prognosis. Therefore, early identification of patients who will recover graft function or undergo graft loss is paramount. Serum factor V and arterial lactate levels can aid in deciding whether to relist patients to retransplantation early in the postoperative period.